Edward N. Libby

University of San Diego — United States

Medicine · Health Sciences

33h-index7.1kcitations159works5.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(63), Lymphoma Diagnosis and Treatment(40), Chronic Lymphocytic Leukemia Research(24), Protein Degradation and Inhibitors(24), Venous Thromboembolism Diagnosis and Management(20)

Publications159 total

Superficial vein thrombosis of the upper extremities: A retrospective analysis of clot progression and role of thrombophilia testing
Blood·2025
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials
Transplantation and Cellular Therapy·2025· 1 cited
Treatment Outcomes By Duffy Genotype in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone or Rvd Plus Autologous Stem Cell Transplantation (ASCT) in the Determination Phase 3 Trial
Transplantation and Cellular Therapy·2025
Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
Blood·2024· 10 cited
Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
Blood·2024Open Access
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
Carolina Digital Repository (University of North Carolina at Chapel Hill)·2024· 2 citedOpen Access
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Blood Advances·2024· 24 citedOpen Access
Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
Blood·2023· 5 cited
Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial
Cancer·2023· 52 citedOpen Access
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Journal of Clinical Oncology·2023· 85 citedOpen Access
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial
The Lancet Oncology·2023· 87 citedOpen Access
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
Blood·2023· 66 citedOpen Access
P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL
HemaSphere·2023· 2 citedOpen Access
P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES
HemaSphere·2023· 1 citedOpen Access
Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) and Lenalidomide (R) Maintenance to Progression in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
Transplantation and Cellular Therapy·2023Open Access
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL
Blood Advances·2022· 2 citedOpen Access
Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial
Blood·2022· 15 cited
Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
Blood·2022· 6 cited
Radiographic Response of Solitary Plasmacytomas After Conformal Radiotherapy May Be Delayed
American Journal of Clinical Oncology·2022· 1 cited
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R<sup>2</sup>) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
Journal of Clinical Oncology·2022· 62 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Andrew J. Cowan(14), Damian J. Green(11), Adam D. Cohen(9), Ajay K. Gopal(8), Paul G. Richardson(8), Brian G. Till(8), David G. Coffey(7), David García(7), David G. Maloney(7), Suzanne Trudel(6), Peter M. Voorhees(6), Ryan D. Cassaday(6), Leona Holmberg(5), Sherilyn A. Tuazon(5), Rakesh Popat(5), Joanna Opalinska(5), Pamela S. Becker(5), Mazyar Shadman(5), Andrei R. Shustov(5), Mary Philip(5)